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background: Growth Differentiation Factor 11 (GDF-11) reverses cardiac hypertrophy in mice (Cell 2013; 153:828-839). These data suggest 
GDF-11 as a potential target for treatment of left ventricular hypertrophy (LVH), but data on GDF-11 in human subjects are lacking. We investigated 
whether circulating GDF-11 levels are associated with LVH in humans.
Methods: Using aptamer-based proteomics technology, we measured serum GDF-11 levels in a cohort of 974 outpatients with stable ischemic 
heart disease (IHD). We assessed the presence of LVH by echocardiography. We used logistic regression models to evaluate the association between 
GDF-11 and prevalence of LVH.
results: LVH was present in 389 participants (40%). Participants in the highest quartile of GDF-11 level were less likely to have LVH compared 
with participants in the lowest quartile (OR 0.63, 95%CI 0.44, 0.91; P=0.01) (Table). After multivariate adjustment, high GDF-11 levels remained 
associated with lower prevalence of LVH (highest vs. lowest quartile OR 0.64, 95%CI 0.41, 1.00; P=0.05).
conclusion: In patients with stable IHD, high levels of GDF-11 are associated with lower prevalence of LVH. In context of prior studies in mice, our 
findings are consistent with GDF-11 as a circulating factor that protects against LVH in humans.
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*Adjusted for sex and race.
†Adjusted for sex, race, age, hypertension, diabetes, history of MI, eGFR, left ventricular ejection fraction, and smoking status.
